SEC Filing Timeline
8-KJun 15, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KJun 10, 2026
Shareholder vote results · Items 5.07
10-QMay 11, 2026
Quarterly report
8-KMay 11, 2026
Earnings release · Items 2.02,9.01
8-KApr 30, 2026
Material agreement · Items 1.01,2.02,9.01
DEFA14AApr 30, 2026
Additional proxy
DEF 14AApr 30, 2026
Proxy statement
424B5Apr 29, 2026
Prospectus / offering
424B5Apr 27, 2026
Prospectus / offering
8-KApr 27, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KApr 10, 2026
Charter/bylaws amendment · Items 5.03,9.01
424B5Mar 02, 2026
Prospectus / offering
8-KMar 02, 2026
Material agreement · Items 1.01,7.01,8.01,9.01
10-KFeb 26, 2026
Annual report
8-KFeb 26, 2026
Earnings release · Items 2.02,9.01
Recent News (Finnhub)
This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target
Intellia Therapeutics: An Overvalued Biotech With Little To No Commercial Potential
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17
Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns